Commentary: preclinical efficacy of immune-checkpoint monotherapy does not recapitulate corresponding biomarkers-based clinical predictions in glioblastoma by Garg et al. (2017). (4th March 2019)

• Record Type: Journal Article
• Authors: Zhai, Lijie; Ladomersky, Erik; Lauing, Kristen L.; Wu, Meijing; Scholtens, Denise M.; Savoor, Rohan; Zhang, Bin; Wu, Jennifer D.; Horbinski, Craig; Lukas, Rimas V.; Binder, David C.; Wainwright, Derek A.
• Is Part Of: Oncoimmunology. Volume 8:Number 3(2019)
• Publication Date: 2019-03-04
• Subjects: IDO -- immunotherapy -- immunosuppression -- brain tumor -- glioblastoma -- Treg; Tumors -- Immunological aspects -- Periodicals; Neoplasms -- therapy -- Periodicals; Immunotherapy -- Periodicals; 616.994
• DOI: 10.1080/2162402X.2018.1548242
• Languages: English
• ISSNs: 2162-402X

Abstract

ABSTRACT: Preclinical modeling and gene expression analyses have yielded distinct observations for the role of immune checkpoint, IDO1, in glioblastoma (GBM). Accordingly, our recent work differs with Garg et al . (2017) with respect to IDO1 among preclinical and bioinformatic GBM datasets. Here, we discuss the methodological differences that affected study interpretation, and potentially, future clinical decision-making for IDO1-targeting approaches against GBM.